About: Efficacy and tolerability of bevacizumab in patients with severe Covid -19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and tolerability of bevacizumab in patients with severe Covid -19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Efficacy and tolerability of bevacizumab in patients with severe Covid -19
Creator	Zhang, Yuan Zhang, Ying Wei, Jie Ji, Xiang Chen, Jun Wang, Hao Li, Yu Xu, Feng Wu, Shuo Canesi, Margherita Damiani, Aondio, Gianmarco Bian, Yuan Cao, Yihai Fumagalli, Alberto Kovacs, Attila Pang, Jiaojiao Revera, Miriam Sui, Wenhai Valmadre, Giuseppe Wang, Bailu Yu, Dexin
source	MedRxiv
abstract	On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesized that the anti-VEGF drug bevacizumab might be beneficial for treating Covid-19 patients. We recruited 26 patients from 2-centers (China and Italy) with confirmed severe Covid-19, with respiratory rate [≥]30 times/min, oxygen saturation [≤]93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100mmHg and [≤]300 mmHg, and diffuse pneumonia confirmed by chest radiological imaging. This trial was conducted from Feb 15 to April 5, 2020, and followed up for 28 days. Relative to comparable control patients with severe Covid-19 admitted in the same centers, bevacizumab showed clinical efficacy by improving oxygenation and shortening oxygen-support duration. Among 26 hospitalized patients with severe Covid-19 (median age, 62 years, 20 [77%] males), bevacizumab plus standard care markedly improved the PaO2/FiO2 ratios at days 1 and 7 (elevated values, day 1, 50.5 [4.0,119.0], p<0.001; day 7, 111.0 [85.0,165.0], p<0.001). By day 28, 24 (92%) patients showed improvement in oxygen-support status, 17 (65%) patients were discharged, and none showed worsen oxygen-support status nor died. Significant reduction of lesion areas and ratios were shown in chest CT or X-ray analysis within 7 days. Of 14 patients with fever, body temperature normalized within 72 hours in 13 (93%) patients. Lymphocyte counts in peripheral blood were significantly increased and CRP levels were markedly decreased as shown in available data. Our findings suggested bevacizumab plus standard care was highly beneficial for treating patients with severe Covid-19. Clinical efficacy of bevacizumab warrants double blind, randomized, placebo-controlled trials.
has issue date	2020-07-29(xsd:dateTime)
bibo:doi	10.1101/2020.07.26.20159756
has license	medrxiv
sha1sum (hex)	42c1043b009a1a458d390cbbd80604814f673d25
schema:url	https://doi.org/10.1101/2020.07.26.20159756
resource representing a document's title	Efficacy and tolerability of bevacizumab in patients with severe Covid -19
resource representing a document's body	covid:42c1043b009a1a458d390cbbd80604814f673d25#body_text
is schema:about of	named entity 'induced' named entity 'confirmed' named entity 'day' named entity 'highly' named entity 'hypothesized' named entity 'care' named entity 'standard' named entity 'patients' named entity 'Efficacy' named entity 'bevacizumab' named entity 'National Health Commission' named entity 'diffuse' named entity 'males' named entity 'severe' named entity 'placebo-controlled' named entity 'standard' named entity 'day' named entity 'April' named entity 'Covid-19' named entity 'shortening' named entity 'severe' named entity 'days' named entity 'patients' named entity 'bevacizumab' named entity 'efficacy' named entity 'median age' named entity 'trials' named entity 'Chinese' named entity 'bevacizumab' named entity 'lesion' named entity 'radiological imaging' named entity 'PaO2/FiO2' named entity 'Italy' named entity '28 days' named entity 'respiratory rate' named entity 'oxygen' named entity 'Covid -19' named entity 'values' named entity 'CRP' named entity 'bevacizumab' named entity 'bevacizumab' named entity 'hypothesis test' named entity 'follow-up' named entity 'Skin rash' named entity 'fever' named entity 'blood urea nitrogen' named entity 'body temperature' named entity 'Red color' named entity 'chest CT' named entity 'wet age-related macular degeneration' named entity 'bevacizumab' named entity 'bevacizumab' named entity 'major surgery' named entity 'inflammation' named entity 'lymphocyte' named entity 'paired t-test' named entity 'Covid' named entity 'arterial blood gas' named entity 'control group' named entity 'Covid-19' named entity 'VEGF' named entity 'fever' named entity 'lungs' named entity 'fever'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software